Nkarta to Participate at Upcoming Investor Conferences

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in three notable investor conferences.

Rhea-AI Summary

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in three notable investor conferences. The events include the SVB Securities Global Biopharma Conference on February 14, 2023, where a fireside chat is slated for 3:40 p.m. ET; the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, with timing to be determined; and the Cowen 43rd Annual Health Care Conference on March 8, 2023, featuring an industry panel discussion at 2:10 p.m. ET. Webcasts of the events will be accessible on Nkarta’s website, with replays available for 90 days.

Argus Session date unavailable

-2.69% session move Open Argus

Details

News Market Reaction – NKTX

The recorded move for NKTX in the trading session of this news was -2.69%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:

SVB Securities Global Biopharma Conference
February 14, 2023
3:40 p.m. ET – fireside chat

H.C. Wainwright Cell Therapy Virtual Conference
February 28, 2023
Time tbd – fireside chat

Cowen 43^rd Annual Health Care Conference
March 8, 2023
2:10 p.m. ET – industry panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences is Nkarta, Inc. participating in February and March 2023?

Nkarta, Inc. is participating in three investor conferences: the SVB Securities Global Biopharma Conference on February 14, 2023, the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, and the Cowen 43rd Annual Health Care Conference on March 8, 2023.

What is the date and time of Nkarta's participation in the SVB Securities Global Biopharma Conference?

Nkarta's participation in the SVB Securities Global Biopharma Conference is scheduled for February 14, 2023, at 3:40 p.m. ET.

Where can I watch Nkarta's investor conference presentations?

Nkarta's investor conference presentations will be available via webcast on the Investors section of Nkarta's website, with replays accessible for approximately 90 days.

What is the focus of Nkarta, Inc.'s therapies?

Nkarta, Inc. focuses on developing engineered natural killer (NK) cell therapies aimed at treating cancer.

When is the Cowen 43rd Annual Health Care Conference?

The Cowen 43rd Annual Health Care Conference will take place on March 8, 2023, with Nkarta participating in an industry panel discussion at 2:10 p.m. ET.